(Nasdaq:BBNX) announced today that it launched Bionic Insights, a new feature for healthcare providers and people with ...

According to MarketsandMarkets™, the Autoinjectors Market is projected to grow from about USD 127.30 billion in 2026 to USD ...

The peptides, which are increasingly marketed as providing longevity and health benefits, were removed in 2023 from the ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

Novo Nordisk’s icodec-abae is now approved in the US for type 2 diabetes only, after a prior rejection partly due to concerns about hypoglycemia in type 1 diabetes.

The FDA’s decision is based on data from the ONWARDS Phase IIIa clinical programme involving nearly 2,680 adults.

Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA ...

Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA study ...

The FDA has approved the first weekly insulin shot for adults with type 2 diabetes, offering a new alternative to daily injections.

The FDA just approved Awiqli, a once-weekly insulin treatment for type 2 diabetes. Awiqli allows patients to shift from daily injections. The effectiveness, safety, and side effects are similar to ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin ...

(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...